REGENXBIO Reports Positive Phase III Duchenne Gene Therapy Results, Eyes Accelerated Approval

summarizeSummary

REGENXBIO reported positive Phase III results for its Duchenne gene therapy, RGX-202, meeting its primary endpoint and showing correlation with functional improvement, paving the way for potential accelerated approval in 2027. The company also announced the lifting of a clinical hold on RGX-121 and expects a $100 million milestone payment from AbbVie.

check_boxKey Events

• Positive Phase III Results for RGX-202

  The pivotal Phase III AFFINITY DUCHENNE® study of RGX-202 met its primary endpoint with high statistical significance (p<0.0001), with 93% of patients achieving microdystrophin expression above 10%. The study also showed a statistically significant correlation between microdystrophin expression and functional improvement.

• Path to Accelerated Approval

  The positive topline data and correlation analysis support REGENXBIO's plan to pursue accelerated approval for RGX-202, with a potential commercial launch targeted for 2027. The FDA has indicated that externally controlled trials may be adequate for demonstrating effectiveness if the treatment effect is sufficiently large.

• Q1 2026 Financial Results

  The company reported cash, cash equivalents, and marketable securities of $150.5 million as of March 31, 2026, down from $240.9 million at year-end 2025. Revenues were $6.4 million, and the net loss was $90.1 million ($1.72 per share). The company expects its cash to fund operations into early 2027.

• FDA Clinical Hold Lifted for RGX-121

  The FDA has lifted the partial clinical hold on clemidsogene lanparvovec (RGX-121), a treatment for Hunter syndrome, providing positive regulatory progress for another pipeline asset.

auto_awesomeAnalysis

REGENXBIO announced highly positive topline results from its pivotal Phase III AFFINITY DUCHENNE® study of RGX-202 for Duchenne Muscular Dystrophy. The trial met its primary endpoint with high statistical significance, showing 93% of patients achieved microdystrophin expression above 10%, and crucially, demonstrated a statistically significant correlation between microdystrophin expression and functional improvement. This data supports a potential accelerated approval in 2027 and is a major de-risking event for the company's lead asset, offering a path to commercialization. This positive clinical development, along with the lifting of a clinical hold on RGX-121 and an expected $100 million milestone payment from AbbVie, provides a significant boost to the company's prospects, especially given previous concerns about its ability to continue as a going concern and its current cash runway into early 2027.